To provide consensus on the clinical use of intravitreal dexamethasone (DEX) implant for the treatment of diabetic macular edema (DME) in Turkey.
Methods
A panel of 22 retina experts prepared 77 statements of recommendation, and 80 retinal specialists practicing in Turkey were chosen to vote either in support or against each one. A Delphi-based method was used through which the ophthalmologists were able to view all of the results anonymously after two rounds and modify their subsequent answers. The survey was conducted via a mini website, and statements without consensus were resent to the specialists with the latest vote results a week later.
Results
A total of 72 ophthalmologists answered the first and second round questions. After the first stage, consensus was achieved on 55 of the statements, leaving 22 without agreement. After the second stage, consensus was reached on 11 of the remaining statements. Strong consensus was achieved on statements regarding the etiopathogenesis of DME and the first-line indications and safety of the DEX implant procedure. The panel recommended the use of DEX implant for patients with an arterial thromboembolic event in the last three months and also agreed that pro re nata DEX implant treatment not only provides better outcomes for DME patients but also reduces the treatment burden for those who could not receive an adequate number of anti-vascular endothelial growth factor (VEGF) injections.
Conclusion
This study provides clinical consensus and recommendations about the use of DEX implant in the clinical practice of DME management in Turkey.
KempenJHO’ColmainBJLeskeMC, et al.The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol2004; 122: 552–563.
2.
YauJWRogersSLKawasakiR, et al.Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012; 35: 556–564.
3.
AcanDCalanMErD, et al.The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. BMC Ophthalmol2018; 18: 91.
4.
ZhangWLiuHAl-ShabraweyM, et al.Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res2011; 2: 96–103.
5.
SolomonSDChewEDuhEJ, et al.Diabetic retinopathy: a position statement by the American diabetes association. Diabetes Care2017; 40: 412–418.
6.
Schmidt-ErfurthUGarcia-ArumiJBandelloF, et al.Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica2017; 237: 185–222.
7.
BoyerDSHopkinsJJSorofJ, et al.Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab2013; 4: 151–169.
8.
NguyenQDBrownDMMarcusDM, et al.Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012; 119: 789–801.
9.
KorobelnikJFDoDVSchmidt-ErfurthU, et al.Intravitreal aflibercept for diabetic macular edema. Ophthalmology2014; 121: 2247–2254.
10.
WellsJAGlassmanARAyalaAR, et al.Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016; 123: 1351–1359.
11.
MitchellPBandelloFSchmidt-ErfurthU, et al.The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011; 118: 615–625.
12.
GonzalezVHCampbellJHolekampNM, et al.Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol2016; 172: 72–79.
13.
BoyerDSYoonYHBelfortRJr., et al.Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014; 121: 1904–1914.
14.
GiovanniniAParravanoMRicciF, et al.Management of diabetic macular edema with intravitreal dexamethasone implants: expert recommendations using a delphi-based approach. Eur J Ophthalmol2019; 29: 82–91.
15.
Garcia LayanaAAdanAAscasoFJ, et al.Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a delphi approach. Eur J Ophthalmol2020; 30: 1042–1052.
16.
AugustinAJFeltgenNHaritoglouC, et al.[Clinical decision making for treatment of diabetic macular oedema with DEX implant: a consensus paper]. Klin Monbl Augenheilkd2021; 238: 73–84.
17.
KodjikianLBaillifSCouturierA, et al.Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study. Eur J Ophthalmol2021: 11206721211052852.
18.
DiamondIRGrantRCFeldmanBM, et al.Defining consensus: a systematic review recommends methodologic criteria for reporting of delphi studies. J Clin Epidemiol2014; 67: 401–409.
19.
FPM. European Guidelines on cardiovascular disease prevention in clinical practice : the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Int J Behav Med2016; 2017: 321–419.
20.
Diabetic Retinopathy Clinical Research N, ElmanMJAielloLPBeckRW, et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010; 117:1064–1077e1035.
21.
KimEJLinWVRodriguezSM, et al.Treatment of diabetic macular edema. Curr Diab Rep2019; 19: 68.
22.
WanTTLiXFSunYM, et al.Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Biomed Pharmacother2015; 74: 145–147.
23.
StewartMW. Corticosteroid use for diabetic macular edema: old fad or new trend?Curr Diab Rep2012; 12: 364–375.
24.
BestALFajnkuchenFNghiem-BuffetS, et al.Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol2018; 2018: 4610129.
25.
LimLSNgWYMathurR, et al.Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol2015; 9: 1715–1718.
26.
RahimyEShahlaeeAKhanMA, et al.Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol2016; 164: 118–127. e112.
27.
Ruiz-MedranoJRodriguez-LeorRAlmazanE, et al.Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: early versus late switch. Eur J Ophthalmol2021; 31: 1135–1145.
28.
BuschCZurDFraser-BellS, et al.Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol2018; 55: 789–796.
29.
Hernandez MartinezAPereira DelgadoESilva SilvaG, et al.Early versus late switch: how long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?Eur J Ophthalmol2020; 30: 1091–1098.
30.
KhanZKuriakoseRKKhanM, et al.Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina2017; 48: 160–166.
31.
KayaMKocakNOzturkT, et al.Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol. Eye (Lond)2021; 35: 777–785.
32.
BandelloFPolitoAPognuzDR, et al.Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol2006; 124: 643–650.
33.
IaconoPParodiMBScaramuzziM, et al.Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol2017; 101: 791–795.
34.
Nguyen-KhoaBAGoehringELWertherW, et al.Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol2012; 12: 11.
